45 / 52
© The Canadian Journal of Urology™; 23(Supplement 1); February 2016
11. Nead, KT, Gaskin G, Chester C et al. Androgen deprivation
therapy and future Alzheimer’s disease risk.
J Clin Oncol
2015
Dec 7. Epub ahead of print.
12. Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S.
Androgen deprivation therapy and risk of acute kidney injury
in patients with prostate cancer.
JAMA
2013;310(3):289-296.
13. Saad F, Eisenberger MA. Introduction—castration resistant
prostate cancer: Arapidly expanding clinical state and a model
for new therapeutic opportunities.
Curr Clin Urol
2014:3-8.
14. Shah S, Ryan C. Abiraterone acetate for castration resistant
prostate cancer.
Expert Opin Investig Drugs
2010;19(4):563-570.
15. Chi K, Hotte SJ, JoshuaAM. Treatment of mCRPC in theAR-axis-
targeted therapy-resistant state.
AnnOncol
2015;26(10):2044-2056.
16. Cancer Care Ontario Formulary October 2015, http://ocp.
cancercare.on.ca/CCO_DrugFormulary/Pages/DfPdfContent.aspx?itemId=101574.
17. Cancer Care Ontario Formulary September 2015, http://ocp.
cancercare.on.ca/CCO_DrugFormulary/Pages/DfPdfContent.aspx?itemId=281003.
18. Saluja R, DeAngelis, C, Emmenegger U. Drug-drug interactions:
an emerging challenge in the contemporary treatment of
castration-resistant prostate cancer. Supplement to Hot Spot,
the newsletter of the Rapid Response Radiotherapy Program
of the Odette Cancer Centre – May 2014.
19. Nilsson S, Franzen L, Parker C et al. Bone-targeted radium-223
in symptomatic, hormone-refractory prostate cancer: A
randomised, multicentre, placebo-controlled phase II study.
Lancet Oncol
2007;8(7):587-594.
20. Fizazi K, CarducciM, SmithMet al. Denosumabversus zoledronic
acid for treatment of bone metastases in men with castration-
resistant prostate cancer: a randomised, double-blind study.
Lancet
2011;377(9768):813-822.
Mak AND Barkin
36